LLS TRP funds high-impact translational research to accelerate new therapies for blood cancers—from novel immunotherapies and targeted strategies (including epigenetic approaches) to safer, more effective stem cell transplantation—moving strong science toward clinical application.
Eligibility criteria
-
Investigator-initiated projects focused on hematologic malignancies (e.g., aggressive and indolent lymphomas, CLL/FL/WM, MPN/MDS/AML/ALL, multiple myeloma, pre-emergent conditions).
-
Emphasis welcomed on novel immunotherapy and immune synapse biology.
-
Up to two Co-PIs allowed; Co-PIs designated at LOI cannot be changed later.
-
Clinical trials are allowable (include a Patient Involvement Plan if PI/Co-PI is on a trial).
-
Applicant and institution must be registered in the LLS Research Portal.
-
International institutions are eligible (U.S. ZIP field optional; leave blank if non-U.S.).
Funding details
-
Total budget: up to 750,000 USD over 3 years (max 250,000 USD per year; total costs).
-
Indirect costs: capped at 10% of the total award (applied per LLS rules).
-
Allowable direct costs include personnel (with caps for post-graduate professional staff), supplies/materials, equipment (>4,000 USD itemized), travel (≤2,000 USD/year), patient care costs, subcontracts, and other justified direct costs.
-
Impermissible: membership dues, tuition, books/journals, and publication costs.
-
Standard project dates: July 1, 2025 – June 30, 2028 (adjust per LLS timeline).
Deadline
-
Letter of Intent (LOI) due: October 16, 2025 by 3:00 pm ET.
-
Full application due (by invitation): January 21, 2026 by 3:00 pm ET.
-
Submit early; portal locks at deadline and late corrections are not permitted.
Where to go for further information
-
Submit & manage applications: LLS Research Portal.
-
Program & portal questions: [email protected]